NasdaqGM - Nasdaq Real Time Price USD

Kymera Therapeutics, Inc. (KYMR)

29.11

+0.54

+(1.89%)

At close: May 7 at 4:00:00 PM EDT

30.45

+1.34

+(4.60%)

Pre-Market: 8:28:26 AM EDT

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. A live webcast of the presentation will be available under “News and Events” in the Investors section

GlobeNewswire yesterday

KYMR
+1.89%
Why Kymera Therapeutics Stock Crushed it This Week

According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (NASDAQ: KYMR) notched an almost 23% share price gain across this week. Kymera is a clinical-stage biotech that specializes in a mechanism known as targeted protein degradation in its medicines. Kymera anticipates that it will be able to report data from the trial at some point in the fourth quarter of this year.

Motley Fool 12 days ago

KYMR
+1.89%
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multi

GlobeNewswire 14 days ago

KYMR
+1.89%
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines

GlobeNewswire 16 days ago

KYMR
+1.89%
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 27 days ago

KYMR
+1.89%
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. “We continue to stay

GlobeNewswire 29 days ago

KYMR
+1.89%
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook

The analysts covering Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) delivered a dose of negativity to shareholders today...

Simply Wall St. 2 months ago

KYMR
+1.89%
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

As you might know, Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) last week released its latest full-year, and things did...

Simply Wall St. 2 months ago

KYMR
+1.89%
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.

Zacks 2 months ago

KYMR
+1.89%
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

KYMR
+1.89%
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

Kymera Therapeutics Inc (KYMR) reports robust financial health and strategic advancements, setting the stage for significant clinical data releases in 2025.

GuruFocus.com 2 months ago

KYMR
+1.89%

SNY
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -15.79% and 43.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

KYMR
+1.89%
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25 KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD ongoing, led by partner Sanofi,

GlobeNewswire 2 months ago

KYMR
+1.89%
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 45th Annual Healthcare Conference in Boston, MA on March 5 at 9:10 a.m. ET;Leerink Partners Global Biopharma Conference in Miami, FL on March 11 at 8:0

GlobeNewswire 2 months ago

KYMR
+1.89%
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register

GlobeNewswire 2 months ago

KYMR
+1.89%
NAYA Biosciences Announces Nomination of New Board Members

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder

GlobeNewswire 2 months ago

NAYA

KYMR
+1.89%

BDTX
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; andOppenheimer 35th Annual Healthcare

GlobeNewswire 3 months ago

KYMR
+1.89%
Kymera Provides Pipeline Objectives for 2025, Stock Gains

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

Zacks 3 months ago

KYMR
+1.89%
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 3 months ago

KYMR
+1.89%

ABUS
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

Groundbreaking therapies for inflammatory diseases, ambitious clinical milestones, and a cash-rich balance sheet fuel investor confidence.

GuruFocus.com 3 months ago

KYMR
+1.89%

Performance Overview

Return	KYMR	S&P 500 (^GSPC)
YTD	-27.64%	-4.26%
1-Year	-24.27%	+8.55%
3-Year	+52.89%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Why Kymera Therapeutics Stock Crushed it This Week

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

NAYA Biosciences Announces Nomination of New Board Members

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

Performance Overview